Traws Pharma reverses to $7.1M Q1 loss as antiviral R&D costs double
Traws Pharma (NASDAQ:TRAW) reported a net loss for the first quarter of 2026 as the company aggressively scaled up investments in its respiratory antiviral pipeline, pivoting away from the profitable metrics recorded in the prior year's opening period.
The Newtown, Pennsylvania-based biopharmaceutical firm posted a net loss of $7.1 million, or ($0.53) per basic and diluted share, for the three months ended March 31, 2026.
This bottom-line performance represents a sharp reversal from the net income of $21.5 million, or $2.17 per basic share, generated during the first quarter of 2025.
The company generated $0.0 million in revenue for the quarter, compared to a nominal $0.06 million in the prior-year period.
The deepening quarterly deficit was primarily driven by a near-doubling of the company's scientific programs.
Research and development (R&D) expenses rose to $4.9 million, up from $2.5 million in the first quarter of 2025, reflecting heightened spending on its lead infectious disease clinical candidates.
Conversely, general and administrative (G&A) overhead declined by $0.7 million year-over-year to $2 million, partially mitigating the pipeline expenditures.
To shore up its capital structure amid escalating operational costs, Traws closed a major private investment in public equity (PIPE) financing arrangement post-quarter-end on April 15, 2026.
The structured deal offers up to $60 million in gross proceeds, consisting of an immediate $10 million upfront cash injection alongside milestone-based and common stock warrants capable of bringing in an additional $50 million if fully exercised.
Management noted that while the company concluded the first quarter with a tight standalone cash position of $3.1 million and a working capital deficit of $7.9 million, the new funding package fundamentally alters its liquidity outlook.
The gross proceeds from the initial PIPE closing are projected to secure Traws Pharma's operational runway into the first quarter of 2027.
On the clinical development front, the fresh capital stack is earmarked to advance the company's lead candidate, tivoxavir marboxil (TXM), an investigational oral therapy designed for influenza prophylaxis.
Traws is progressing TXM through an open Phase 1 bridging study in Australia to support a planned single-dose, once-monthly influenza prophylaxis human challenge trial via hVIVO in the United Kingdom, slated to begin in the second quarter of 2026.
Simultaneously, executives confirmed they are actively preparing to engage with the U.S. Food and Drug Administration (FDA) to resolve an outstanding clinical hold on the drug's domestic Investigational New Drug (IND) application stemming from previous toxicology concerns.